NPCENPCEHealthcare · Medical Devices

NPCE Stock Forecast: NeuroPace, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.97
−2.09% on the day

The 10 Wall Street analysts covering NeuroPace, Inc. hold a median 12-month price target of $12 — +50.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 73 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$273.9M
Ticker Nerd rank
73/ 100
Median analyst target
$12
Analysts covering
10
Revenue$22.8M−3.0% y/y
Operating income−$5.1M
Net income−$6.2M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.4%
1M
−41.0%
YTD
−48.4%
1Y
−41.0%
From 52W high
−58.7%
From 52W low
+5.4%
$8
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores NeuroPace, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
73/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
81
Volatility
75
Accruals
73
Growth
65
Value
62
Issuance
60
Momentum
59
Revisions
28

Quality (81): The business earns solid, repeatable profits on what it owns.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NPCE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NPCE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26NPCEHigh $22Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
6
Buy
4
Hold
0
Sell
$8
Low
$12
Median
$22
High

The green dot is the last close — the median target sits +50.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
16 Nov 2026HC Wainwright & Co.MaintainsBuy$20 → $12
16 Nov 2026MizuhoMaintainsOutperform$22 → $12
13 Nov 2026Cantor FitzgeraldMaintainsOverweight$21 → $12
13 Nov 2026JP MorganDowngradeNeutral$20 → $9.00
13 Nov 2026KeybancMaintainsOverweight$18 → $14
13 Nov 2026Leerink PartnersDowngradeMarket Perform$7.00
18 Sept 2026KeybancInitiatesOverweight$18
29 July 2026HC Wainwright & Co.ReiteratesBuy$20
23 July 2026MizuhoInitiatesOutperform$22
15 May 2026HC Wainwright & Co.MaintainsBuy$19 → $20
27 Jan 2026HC Wainwright & Co.MaintainsBuy—
16 Dec 2025UBSMaintainsBuy—
10 Dec 2025JP MorganMaintainsOverweight—
5 Nov 2025JP MorganMaintainsOverweight—
5 Nov 2025Wells FargoMaintainsOverweight—
13 Aug 2025Wells FargoMaintainsOverweight—
28 May 2025HC Wainwright & Co.InitiatesBuy—
14 May 2025Cantor FitzgeraldReiteratesOverweight—
14 May 2025JP MorganMaintainsOverweight—
14 Apr 2025Cantor FitzgeraldMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NPCE.

Market Radar

This page is one stock. Monday covers all of them.

NPCE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NPCE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, NeuroPace, Inc. returned −41.0% against +6.9% for the S&P 500, dividends included.

NPCE vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26NPCES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NPCE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.6×

Cheaper than 41% of US stocks

Price / book
23.8×

Cheaper than 3% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−1.1%

Higher than 27% of US stocks

Earnings growth (YoY)
—
Gross margin
82.8%

Higher than 93% of US stocks

Operating margin
−9.5%

Higher than 26% of US stocks

Net margin
−17.7%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−97.0%

Higher than 14% of US stocks

Return on assets
−6.3%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeuroPace, Inc. has a market value of $273.9M and an enterprise value of $294.2M.

  • Revenue in the twelve months to 30 June 2026: $98.8M. The latest quarter shrank 3.0% year on year.

  • Net income over the same four quarters: −$19.1M, a −19.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.57.

  • Free cash flow in the twelve months to 30 June 2026: −$11.6M.

  • NeuroPace, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 34.3M.

  • NeuroPace, Inc. employs 216 people — $458K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

NPCE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NPCENeuroPace, Inc.$273.9M73
TMCITreace Medical Concepts, Inc.$274.6M55
INFUInfuSystem Holdings, Inc.$285.8M100
LABStandard BioTools, Inc.$246.1M41
SSIISS Innovations International, Inc.$245.9M11
OFIXOrthofix Medical, Inc.$240.4M60
CLPTClearPoint Neuro, Inc.$221.5M29

Take a look at NPCE’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own NeuroPace, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NPCE

What is the NPCE stock price forecast for 2026-2027?

The 10 Wall Street analysts covering NeuroPace, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NPCE stock a buy right now?

Of the 10 analysts covering NeuroPace, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeuroPace, Inc. 73 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NPCE?

As at 21 Nov 2026, NeuroPace, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (81 of 100).

Will NPCE stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +50.6% from the last close, and Ticker Nerd's factor model ranks NeuroPace, Inc. 73 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NPCE stock forecast for 2030?

No analyst covering NeuroPace, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NPCE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.

How has NPCE stock performed over the past year?

NeuroPace, Inc. returned -41.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeuroPace, Inc. do?

NeuroPace, Inc. is a medical device company focused on brain-responsive neuromodulation for people living with epilepsy. Its core RNS System is an implantable platform designed to detect abnormal brain activity and deliver targeted stimulation in response, helping physicians manage medically refractory focal epilepsy.

Company

About NeuroPace, Inc.

NeuroPace, Inc. is a medical device company focused on brain-responsive neuromodulation for people living with epilepsy. Its core RNS System is an implantable platform designed to detect abnormal brain activity and deliver targeted stimulation in response, helping physicians manage medically refractory focal epilepsy. The company’s product portfolio includes the RNS neurostimulator, depth and cortical strip leads, and accompanying patient monitoring and programming tools that support long-term therapy and remote clinical review. NeuroPace serves hospitals and epilepsy care centers, with its technology used in specialized neurology settings where individualized treatment is critical. The company operates in the neuromodulation and epilepsy treatment markets, where it plays a distinct role by combining continuous brain signal monitoring with responsive therapy in a single commercial system.

CEO Mr. Joel D. Becker · 216 employees · United States · https://www.neuropace.com